Search
Now showing items 1-1 of 1
Different mechanisms for resistance to trastuzumab versus lapatinib in her2- positive breast cancers - role of estrogen receptor and her2 reactivation
(Springer Nature, 2011-11-28)
Introduction: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here we ...